These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6460092)

  • 21. Zinc deficiency, acrodermatitis enteropathica, optic atrophy, subacute myelo-optic neuropathy, and 5,7-dihalo-8-quinolinols.
    Sturtevant FM
    Pediatrics; 1980 Mar; 65(3):610-3. PubMed ID: 6444713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physical Disabilities Related to the Depressive Mental States of Japanese Patients with Subacute Myelo-optico-neuropathy.
    Konishi T
    Intern Med; 2018 Sep; 57(18):2641-2645. PubMed ID: 29780125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clioquinol neurotoxicity: an overview.
    Clifford Rose F; Gawel M
    Acta Neurol Scand Suppl; 1984; 100():137-45. PubMed ID: 6237543
    [No Abstract]   [Full Text] [Related]  

  • 24. Diminished skin vasodilator response to local heating in patients with long-standingsubacute myelo-optico-neuropathy.
    Yamanaka Y; Asahina M; Akaogi Y; Koyama Y; Hattori T
    J Neurol Sci; 2007 Sep; 260(1-2):214-8. PubMed ID: 17572442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Aggravation of Depression with Aging in Japanese Patients with Subacute Myelo-optico-neuropathy (SMON).
    Konishi T; Hayashi K; Sugiyama H
    Intern Med; 2017 Aug; 56(16):2119-2123. PubMed ID: 28781313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prospective study on the side-effects of the clioquinol preparation mexaform with special reference to subacute myelo-optic neuropathy].
    Bezjak B; Breintenfeld V; Schönwald S; Car V; Puskarić-Hamel N; Vrancić J; Hotujac L
    Lijec Vjesn; 1974 Sep; 96(9):553-6. PubMed ID: 4281043
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.
    Baumgartner G; Gawel MJ; Kaeser HE; Pallis CA; Rose FC; Schaumburg HH; Thomas PK; Wadia NH
    J Neurol Neurosurg Psychiatry; 1979 Dec; 42(12):1073-83. PubMed ID: 230316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of neurological symptoms related to hip fracture in a 29-year longitudinal study of subacute myelo-optic-neuropathy (SMON)].
    Konagaya M; Kuru S; Konagaya Y
    Nihon Ronen Igakkai Zasshi; 2010; 47(5):445-51. PubMed ID: 21116089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloneuropathy in dogs induced by iodoxyquinoline.
    Tateishi J; Ikeda H; Saito A; Kuroda S; Otsuki S
    Neurology; 1972 Jul; 22(7):702-9. PubMed ID: 4673252
    [No Abstract]   [Full Text] [Related]  

  • 30. Myelo-optic neuropathy induced by clioquinol in animals.
    Tateishi J; Kuroda S; Saito A; Otsuki S
    Lancet; 1971 Dec; 2(7736):1263-4. PubMed ID: 4143622
    [No Abstract]   [Full Text] [Related]  

  • 31. Subacute myelo-optico-neuropathy (SMON).
    Nelson E
    Ann Intern Med; 1972 Sep; 77(3):468-70. PubMed ID: 4262315
    [No Abstract]   [Full Text] [Related]  

  • 32. [Epidemiological studies on subacute myelo-optico neuropathy (SMON) in the town of Yubara, Japan. 3].
    Aoyama H; Oira M; Ota T; Yoshioka S; Yoshida T
    Nihon Eiseigaku Zasshi; 1970 Dec; 25(5):468-71. PubMed ID: 4251106
    [No Abstract]   [Full Text] [Related]  

  • 33. [Neuropathology of subacute myelo-optico-neuropathy, (SMON)].
    Shiraki H; Oda M
    Saishin Igaku; 1969 Dec; 24(12):2479-509. PubMed ID: 5363408
    [No Abstract]   [Full Text] [Related]  

  • 34. Founder genetic variants of ABCC4 and ABCC11 in the Japanese population are not associated with the development of subacute myelo-optico-neuropathy (SMON).
    Matsumoto H; Sasai H; Kawamoto N; Katsuyama M; Minamiyama M; Kuru S; Fukao T; Ohnishi H;
    Mol Genet Genomic Med; 2022 Jan; 10(1):e1845. PubMed ID: 34951141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The prevalence of dementia in subacute myelo-optico-neuropathy (SMON) patients who underwent medical checkups].
    Saito Y; Sakai K; Konagaya M
    Nihon Ronen Igakkai Zasshi; 2016; 53(2):152-7. PubMed ID: 27250222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss-of-function polymorphisms in NQO1 are not associated with the development of subacute myelo-optico-neuropathy.
    Matsumoto H; Sasai H; Kawamoto N; Katsuyama M; Minamiyama M; Kuru S; Fukao T; Ohnishi H;
    Mol Genet Genomic Med; 2024 Jun; 12(6):e2470. PubMed ID: 38860482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban.
    Konagaya M; Matsumoto A; Takase S; Mizutani T; Sobue G; Konishi T; Hayabara T; Iwashita H; Ujihira T; Miyata K; Matsuoka Y
    J Neurol Sci; 2004 Mar; 218(1-2):85-90. PubMed ID: 14759638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Subacute myelo-optical neuropathy (SMON) in thallium poisoning].
    Beer G; Schwartz RB
    Nervenarzt; 1982 Aug; 53(8):451-4. PubMed ID: 7133245
    [No Abstract]   [Full Text] [Related]  

  • 39. Experimental myelo-optic neuropathy induced by clioquinol.
    Tateishi J; Kuroda S; Saito A; Otsuki S
    Acta Neuropathol; 1973; 24(4):304-20. PubMed ID: 4269146
    [No Abstract]   [Full Text] [Related]  

  • 40. Sleep problems in subacute myelo-optico neuropathy (SMON).
    Hishikawa N; Takemoto M; Sato K; Yamashita T; Ohta Y; Sakai K; Abe K
    J Clin Neurosci; 2019 Oct; 68():128-133. PubMed ID: 31326286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.